Your browser doesn't support javascript.
loading
Novel immunotherapeutic approaches for pediatric classical Hodgkin lymphoma: Nivolumab or brentuximab vedotin with the AVD regimen.
Okeleji, Olayinka; Gibson, Amber; Nunez, Cesar; Garcia, Miriam B; Roth, Michael; Cuglievan, Branko; McCall, David.
Afiliação
  • Okeleji O; Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Gibson A; Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Nunez C; Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Garcia MB; Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Roth M; Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Cuglievan B; Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • McCall D; Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Pediatr Blood Cancer ; 71(8): e31091, 2024 Aug.
Article em En | MEDLINE | ID: mdl-38840433
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Hodgkin / Protocolos de Quimioterapia Combinada Antineoplásica / Nivolumabe / Brentuximab Vedotin Limite: Adolescent / Child / Female / Humans / Male Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Hodgkin / Protocolos de Quimioterapia Combinada Antineoplásica / Nivolumabe / Brentuximab Vedotin Limite: Adolescent / Child / Female / Humans / Male Idioma: En Ano de publicação: 2024 Tipo de documento: Article